Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England
read more
Citations
North West London Covid-19 Vaccination Programme: Real-world evidence for Vaccine uptake and effectiveness
Effectiveness of ChAdOx1 nCOV-19 Vaccine: Experience of a tertiary care institute
Effects of BNT162b2 mRNA vaccine on Covid-19 infection and hospitalisation among older people: matched case control study for England
Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model
Covid-19: Single dose of Pfizer and Oxford vaccines cuts risk of hospital admission by 80% in over 80s, data suggest.
References
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Related Papers (5)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Frequently Asked Questions (10)
Q2. What are the future works in "Early effectiveness of covid-19 vaccination with bnt162b2 mrna vaccine and chadox1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in england" ?
Further evidence is needed on the duration of any effect and the effect against asymptomatic infection and transmission and the four UK nations will work closely to develop and share evidence on this as it becomes available. What this study adds: • A single dose of either vaccine provides significant protection against COVID-19 and further protection against severe disease lasting at least 6 weeks, including against the UK variant of concern.
Q3. How long after vaccination did the effectiveness of the ChAdOx1 vaccine increase?
With the ChAdOx1 vaccine, vaccine effects were seen from 14-20 days after vaccination reaching an effectiveness of 60% (95%CI 41-73%) from 28-34 days and further increasing to 73% (95%CI 27-90%) from day 35 onwards.
Q4. What was the effect of the BNT162b2 vaccine on the symptomatic ?
On top of the protection against symptomatic disease, cases who had been vaccinated with one dose of BNT162b2 had an additional 43% (95%CI 33-52%) lower risk of emergency hospitalisation and an additional 51% (95%CI 37-62%) lower risk of death.
Q5. What is the effect of the vaccines against symptomatic disease?
Vaccination with either a single dose of BNT162b2 or ChAdOx1 COVID-19 vaccination was associated with a significant reduction in symptomatic SARS-CoV2 positive cases in older adults with even greater protection against severe disease.
Q6. how effective is a single dose of bnt162b2?
Combined with the effect against symptomatic disease, this indicates that a single dose of either vaccine is approximately 80% effective at preventing hospitalisation and a single dose of BNT162b2 is 85% effective at preventing death with COVID-19.
Q7. How long after vaccination did the effectiveness of the vaccine reach 70%?
Vaccine effects were noted from 10-13 days after vaccination, reaching an effectiveness of 70% (95% CI 59-78%) from 28-34 days, then plateauing.
Q8. How many adults in England have been tested for COVID-19?
Test negative case control designCommunity COVID-19 PCR testing in EnglandAll adults in England aged 70 years and older (over 7.5 million).
Q9. What is the effect of the second dose of BNT162b2 on symptomatic?
A second dose of BNT162b2 provides further protection against symptomatic disease but second doses of ChAdOx1 have not yet been rolled out in England.
Q10. How did the PCR test confirm the risk of COVID-19?
Individuals aged >=80 years vaccinated with BNT162b2 prior to 4th January, had a higher odds of testing positive in the first 9 days after vaccination (odds ratio up to 1.48, 95%CI 1.23-1.77), indicating that those initially targeted had a higher underlying risk of infection.